CA2390857A1 - Inhibiteurs d'agregation plaquettaire induite par le collagene - Google Patents

Inhibiteurs d'agregation plaquettaire induite par le collagene Download PDF

Info

Publication number
CA2390857A1
CA2390857A1 CA002390857A CA2390857A CA2390857A1 CA 2390857 A1 CA2390857 A1 CA 2390857A1 CA 002390857 A CA002390857 A CA 002390857A CA 2390857 A CA2390857 A CA 2390857A CA 2390857 A1 CA2390857 A1 CA 2390857A1
Authority
CA
Canada
Prior art keywords
platelet aggregation
collagen
compound
induced platelet
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390857A
Other languages
English (en)
Inventor
Fatih M. Uckun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2390857A1 publication Critical patent/CA2390857A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention concerne une méthode thérapeutique utilisée pour traiter ou prévenir un état pathologique d'agrégation plaquettaire chez un sujet. Cette méthode consiste à administrer une quantité pharmaceutiquement efficace d'un composé ou d'une composition inhibant l'agrégation plaquettaire induite par la tyrosine kinase de Bruton et par le collagène. L'état pathologique d'agrégation plaquettaire englobe les maladies cardio-vasculaires, hématopoïétiques et les maladies vasculaires cérébrales.
CA002390857A 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene Abandoned CA2390857A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16810399P 1999-11-30 1999-11-30
US60/168,103 1999-11-30
PCT/US2000/042370 WO2001041754A2 (fr) 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene

Publications (1)

Publication Number Publication Date
CA2390857A1 true CA2390857A1 (fr) 2001-06-14

Family

ID=22610139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390857A Abandoned CA2390857A1 (fr) 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene

Country Status (5)

Country Link
EP (1) EP1235567A2 (fr)
JP (1) JP2003516351A (fr)
AU (1) AU4508601A (fr)
CA (1) CA2390857A1 (fr)
WO (1) WO2001041754A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931733A4 (fr) 2005-09-28 2009-11-25 Biovascular Inc Methodes et compositions servant a bloquer l'adherence plaquettaire et cellulaire, la migration cellulaire et l'inflammation
CN101421269A (zh) 2006-01-13 2009-04-29 环状药物公司 酪氨酸激酶抑制剂及其用途
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
PE20151495A1 (es) 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas
EP3027192A4 (fr) 2013-08-02 2017-03-22 Pharmacyclics, LLC Méthodes permettant de traiter des tumeurs solides
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
EP4115886A1 (fr) 2013-10-25 2023-01-11 Pharmacyclics LLC Procédés de traitement et de prévention de la maladie du greffon contre l'hôte
WO2015143400A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Mutations de phospholipase c gamma 2 et associées aux résistances
CA2959602A1 (fr) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
WO2016022942A1 (fr) 2014-08-07 2016-02-11 Pharmacyclics Llc Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton
RU2017133990A (ru) 2015-03-03 2019-04-05 Фармасайкликс Элэлси Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE69918089T2 (de) * 1998-04-17 2005-07-14 Parker Hughes Institute, St. Paul Btk inhibitoren und verfahren zur identifizierung und verwendung
US6306897B1 (en) * 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK

Also Published As

Publication number Publication date
WO2001041754A2 (fr) 2001-06-14
JP2003516351A (ja) 2003-05-13
EP1235567A2 (fr) 2002-09-04
AU4508601A (en) 2001-06-18
WO2001041754A8 (fr) 2003-10-23
WO2001041754A3 (fr) 2002-03-21
WO2001041754A9 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
US6635651B2 (en) Inhibitors of thrombin induced platelet aggregation
CA2390857A1 (fr) Inhibiteurs d'agregation plaquettaire induite par le collagene
DE69924500T2 (de) Chinazolinderivate
EP1364659B1 (fr) Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
US6248790B1 (en) Treatment of inflammation with 2,4,6-trihydroxy-alpha-rho-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives
RU2407523C2 (ru) Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности
AU2015314772B2 (en) Compositions and methods for treatment of prostate carcinoma
WO2002043735A1 (fr) Inhibiteurs d'agregation de plaquettes induite par la thrombine
US6608107B2 (en) Methods and compositions to treat conditions associated with neovascularization
US20020169207A1 (en) Inhibiting collagen-induced platelet aggregation
JPWO2003024446A1 (ja) 酸化ストレス抑制剤および酸化ストレスの測定方法
CN109761958A (zh) 法舒地尔复合盐及其制备方法和用途
EP0928191B1 (fr) Compositions pharmaceutiques renfermant des derives de s-alkylisothiouronium
US20040034045A1 (en) Inhibitors of thrombin induced platelet aggregation
MXPA05005307A (es) Metodo para el tratamiento del infarto al miocardio.
TW201625238A (zh) 抗血小板劑及其用途
Canga et al. Hypersensitivity to methoxamine in atria isolated from streptozotocin-induced diabetic rats.
Yamazaki et al. Enhancement of ADP-induced platelet aggregation by adrenaline in vivo and its prevention
DE69826287T2 (de) Verwendung von phospholambanhemmer zur steigerung der koronäre durchblutung
JP2004002370A (ja) 重症セプシス予防治療剤
Parker et al. Verapamil attenuates lung vascular responses to endotoxin in sheep
RU2430724C2 (ru) Комбинированный противотуберкулезный препарат
Secrest et al. Hypotensive properties of the protein kinase inhibitor, staurosporine, in normotensive and spontaneously hypertensive rats
US20220226265A1 (en) Methods of controlling myocardial blood flow
US20220202801A1 (en) Use of compound in preparation of drug for treating atherosclerosis

Legal Events

Date Code Title Description
FZDE Dead